久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

'First of its kind' treatment for psoriasis born in China

By Jiang Wei and Li Danqing | chinadaily.com.cn | Updated: 2019-08-02 16:33
Share
Share - WeChat
[Photo/Official website of Wenfeng Tianji Pharma Ltd]

On July 12, the Ministry of Science and Technology said Benvitimod cream used for treating mild to moderate psoriasis had been approved by the National Medical Products Administration, China Economy Weekly reported.

The cream is a global first-in-class drug for the disease developed by Beijing Wenfeng Tianji Pharma Ltd and supported by China's major new drug development program.

Benvitimod is categorised as a "first-in-class" drug, as it uses a new and unique mechanism of action for treating a medical condition. Such drugs are considered to be at the highest-level in terms of breakthrough in the pharmaceutical industry.

The birth of China-made Benvitimod highlights the fast development of an innovation-driven bio-pharmaceutical industry, said Song Ruilin, executive president of China Pharmaceutical Innovation and Research Development Association, at a conference on drug innovation and development on July 16.

Psoriasis is a chronic skin condition that can cause red, scaly patches of skin to appear and there is no cure. More than eight million people in China and more than 125 million worldwide suffer from psoriasis.

Calcipotriol, a form of vitamin D, is the first choice for many patients. It is called the gold-standard therapy for psoriasis patients. Compared with Calcipotriol, Benvitimod should be called the diamond-standard therapy, industry insiders said.

Chen Genghui

The Phase III clinical trial showed that Benvitimod has the same and even better curative effect as Calcipotriol, according to the Ministry of Science and Technology. There were no systemic adverse reaction in Phase III study, and Benvitimod has significant advantages over Calcipotriol as it has a rapid onset of effect and long duration of action, as well as a low recurrence rate when patients stop using the medicine. 

Behind the new drug are years of continuous efforts by Chen Genghui, co-inventor of Benvitimod and CEO of Beijing Wenfeng Tianji Pharma Ltd, and Zhang Jianzhong, head of the dermatology department of Peking University People's Hospital, who led the clinical trial of Benvitimod.

In 1999, Chen Genghui's team obtained the patent for Benvitimod. After 10 years of research and development of Benvitimod, Chen received approval to begin clinical trials in 2009.

After dermatologists of several top hospitals turned him down, he met Zhang Jianzhong at Peking University People's Hospital.

"At first, I also doubted what he said," Zhang said, "Over the years, I have seen too many people claiming to have the cure to psoriasis." But ambition and tenacity eventually brought the two together.

Between 2009 and 2016, Zhang led the clinical trial of Phases I, II and III on more than 1,200 patients. The Phase III clinical trial covered more than 730 patients from 22 major hospitals across China.

Zhang Jianzhong

During the Phase III clinical trial, the Center for Drug Evaluation under NMPA required them to compare Benvitimod with the gold-standard Calcipotriol and conduct a double blind experiment. "When the result was announced, my heart was about to pop out," said Chen. The double blind experiment showed that Benvitimod is more effective.

At the annual meeting of American Academy of Dermatology in 2017, Zhang was invited to deliver a speech on their research on Benvitimod, drawing much attention from international counterparts.

"New drug research and development is mainly conducted in Western countries, but China also has advantages in some domains, like Benvitimod," said Zhang. "We should have faith in ourselves."

Researching and developing new drugs is widely considered to be the biggest gamble in the world. A report issued by Deloitte shows that the spending on a new drug, from research and development to putting it on sale, has risen from $1.2 billion in 2010 to $2 billion in 2017.

"The success rate in the pharmaceutical industry is 0.01 percent, and the chance of being rated as a first-in-class drug shrinks to 0.003 percent," Chen said.

"I never gave up because I always had faith that the drug is going to work," Chen said. "I thought, when we succeed, future generations will always remember Benvitimod cream is developed by the Chinese."

On July 19, the production of Benvitimod cream officially began.

"Theoretically speaking, doctors will be able to write prescriptions for the Benvitimod in the very near future," Chen said.

Man uses skill to carve out good living

Firefighters rescue 82-year-old man who went missing in deep mountains

Band of brothers battles solitude, wind to transform desert

Chinese treatment cures Pakistani girl

Firefighters rescue 2-year-old from septic tank in Ningxia

18-year-old honored for saving classmate's life

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 乱人伦中文视频在线 | 久久99国产精品久久99无号码 | 萌白酱喷水福利视频在线 | 欧美日韩乱国产 | 怡红院在线a男人的天堂 | 99视频在线精品免费 | 欧洲精品一区二区三区在线观看 | 一本一本久久a久久精品综合麻豆 | 亚洲欧美一区二区三区在饯 | 国产美女主播一级成人毛片 | 欧美日韩专区国产精品 | 干综合网 | 亚洲日韩视频 | 九九久久国产精品 | 九九在线精品视频播放 | 亚洲精品久久一区影院 | 人人爽人人香蕉 | 欧美aaaa在线观看视频免费 | 人操人碰| 国产成人精品免费视 | 国产三级在线 | 一级做a爰片欧美一区 | 玖草在线视频 | 欧美成人猛男性色生活 | 99国产精品免费观看视频 | 女人让男人桶的小视频 | 国产精品免费_区二区三区观看 | 国产一级毛片卡 | 日本道在线播放 | 午夜福利国产一级毛片 | 国产成人在线视频播放 | 国产一二三区在线 | 日韩一区国产二区欧美三 | 日韩在线观看视频免费 | 亚洲国产精品线观看不卡 | 亚洲欧美国产日韩天堂在线视 | 亚洲精品国产一区二区图片欧美 | 亚洲精品在线视频 | 99国产精品久久久久久久成人热 | 真正免费一级毛片在线播放 | 亚洲人成高清 |